A major new review from the Cochrane Collaboration has reignited debate around anti-amyloid therapies for Alzheimer’s disease, prompting strong responses from researchers, charities and patient advocacy organisations across the UK.
The review, which analysed data from 17 clinical trials involving more than 20,000 participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease, concluded that “the absolute effects of anti-amyloid drugs on cognitive decline and dementia severity were absent or trivial”. The review also highlighted increased risks of brain swelling and bleeding associated with these treatments.
These conclusions have generated significant concern across the dementia research community, particularly because many experts believe the review does not fully reflect the progress made by newer anti-amyloid medicines.
Concerns Over “Pooled Data”
One of the strongest criticisms centres on the way the review grouped together results from 17 separate trials, of which 15 were either unsuccessful or discontinued.
Leading dementia research organisations argued that combining older failed treatments with newer medicines such as Lecanemab and Donanemab creates a misleading overall picture.
ReMind UK Research & Medical Director, Dr Tomas Welsh responds;
ReMindUK welcomes continued discussion and scrutiny of emerging treatments for Alzheimer’s disease, alongside careful evaluation of the evidence supporting them. It is important, however, that reviews of anti-amyloid therapies clearly distinguish between earlier treatments that were unsuccessful in late-stage trials and newer medicines that have demonstrated measurable clinical benefit.
Dr Welsh continues, ” Experts have noted that combining these different groups of drugs may limit how accurately the current evidence is represented.
In particular, Lecanemab and Donanemab have been shown to slow disease progression in people with early Alzheimer’s disease. While these treatments are not a cure and will not be the whole answer to tackling Alzheimer’s, they represent meaningful scientific progress and an important step forward for patients and families. More broadly, Alzheimer’s research is advancing rapidly, with a growing number of clinical trials exploring a wide range of biological pathways and therapeutic approaches.
While important discussions remain around implementation, access and long-term impact, there is broad agreement on one central issue: people affected by Alzheimer’s disease urgently need effective new treatment options.”
While these treatments are not a cure and will not be the whole answer to tackling Alzheimer’s, they represent meaningful scientific progress and an important step forward for patients and families.
Protecting Hope and Future Research
There is also concern that headlines suggesting anti-amyloid drugs are ineffective could discourage participation in dementia clinical trials at a time when research participation is urgently needed.
Researchers stress that failed trials are part of scientific progress. Understanding what does not work helps improve the next generation of treatments. New late-stage trials are already underway, building on lessons learned from earlier studies.
There is broad agreement across the sector that anti-amyloid drugs are not a silver bullet. They come with risks, access challenges and important questions around long-term impact. But most experts also agree they should not be viewed as the end of the road.
For people living with Alzheimer’s disease and their families, the urgent need for better treatment options remains unchanged. The challenge now is ensuring that scientific debate reflects the full complexity of the evidence, and does not undermine the hope that improved treatments are on the horizon.
Take part in dementia research
More news & views
Lifelong learning and brain health: Building your cognitive reserve
Education, intellectually stimulating occupations, and mentally challenging activities throughout life are thought to contribute to cognitive reserve. Continuous learning, problem solving and being mentally active can take many forms. A perfect example of participating in a mentally challenging activity would be to learn a new musical instrument, which incorporates multiple cognitive skills.
READ-OUT study’s 1000th participant recruited at ReMind UK
Bob became the 1,000th volunteer to join the READ-OUT trial, an important milestone that shows the difference people can make by taking part in clinical research. After being diagnosed with mild cognitive impairment (MCI), he chose to take part in the READ-OUT trial, a major national dementia research study exploring whether blood tests could help diagnose dementia earlier and more accurately. Bob said that if his experience could help others facing the same uncertainty, it was worth it.
Jon Snow’s story highlights the importance of talking about Alzheimer’s
Broadcaster Jon Snow has spoken publicly about living with Alzheimer’s disease, sharing his diagnosis in the hope of raising awareness and reducing stigma around dementia. Jon Snow’s experience of living with Alzheimer’s will be explored in a powerful new documentary, Jon Snow: A Last Big Story, produced by Basement Films and airing on Channel 4 on Saturday, 20 June 2026